Abstract:While highly effective at killing Gram-positive bacteria, auranofin lacks significant activity against Gram-negative species for reasons that largely remain unclear. Here, we aimed to elucidate the molecular mechanisms underlying the low susceptibility of the Gram-negative model organism Escherichia coli to auranofin when compared to the Gram-positive model organism Bacillus subtilis. The proteome response of E. coli exposed to auranofin suggests a combination of inactivation of thiol-containing enzymes and the induction of systemic oxidative stress. Susceptibility tests in E. coli mutants lacking proteins upregulated upon auranofin treatment suggested that none of them are directly involved in E. coli's high tolerance to auranofin. E. coli cells lacking the efflux pump component TolC were more sensitive to auranofin treatment, but not to an extent that would fully explain the observed difference in susceptibility of Gram-positive and Gram-negative organisms. We thus tested whether E. coli's thioredoxin reductase (TrxB) is inherently less sensitive to auranofin than TrxB from B. subtilis, which was not the case. However, E. coli strains lacking the low-molecular-weight thiol glutathione, but not glutathione reductase, showed a high susceptibility to auranofin. Bacterial cells expressing the genetically encoded redox probe roGFP2 allowed us to observe the oxidation of cellular protein thiols in situ. Based on our findings, we hypothesize that auranofin leads to a global disturbance in the cellular thiol redox homeostasis in bacteria, but Gram-negative bacteria are inherently more resistant due to the presence of drug export systems and high cellular concentrations of glutathione.IMPORTANCEAuranofin is an FDA-approved drug for the treatment of rheumatoid arthritis. However, it has also high antibacterial activity, in particular against Gram-positive organisms. In the current antibiotics crisis, this would make it an ideal candidate for drug repurposing. However, its much lower activity against Gram-negative organisms prevents its broad-spectrum application. Here we show that, on the level of the presumed target, there is no difference in susceptibility between Gram-negative and Gram-positive species: thioredoxin reductases from both Escherichia coli and Bacillus subtilis are equally inhibited by auranofin. In both species, auranofin treatment leads to oxidative protein modification on a systemic level, as monitored by proteomics and the genetically encoded redox probe roGFP2. The single largest contributor to E. coli's relative resistance to auranofin seems to be the low-molecular-weight thiol glutathione, which is absent in B. subtilis and other Gram-positive species.

Auranofin induces disulfide bond-mimicking S-Au-S bonds in protein thiol pairs

Comparison of the mechanism of antimicrobial action of the gold(I) compound auranofin in Gram-positive and Gram-negative bacteria

S-Se oxidative addition to auranofin derivatives: A theoretical DFT study

Novel Insights into Redox-Based Mechanisms for Auranofin-Induced Rapid Cancer Cell Death

ESI MS studies highlight the selective interaction of Auranofin with protein free thiols.

Auranofin Targeting the NDM-1 Beta-Lactamase: Computational Insights into the Electronic Configuration and Quasi-Tetrahedral Coordination of Gold Ions

Molecular Mechanisms and Clinical Implications of the Gold Drug Auranofin

Targeting the Thioredoxin Reductase-Thioredoxin System from Staphylococcus Aureus by Silver Ions

Ligand supplementation restores the cancer therapy efficacy of an antirheumatic drug auranofin from serum inactivation

Adaptation mechanisms of Clostridioides difficile to auranofin and its impact on human gut microbiota

Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased S. Aureus and E. Faecalis.

Synthesis and Molecular Recognition Studies on Small-Molecule Inhibitors for Thioredoxin Reductase

The mechanism of action of auranofin analogs in B. cenocepacia revealed by chemogenomic profiling

Auranofin Has Advantages over First-Line Drugs in the Treatment of Severe <i>Streptococcus suis</i> Infections

Antibiofilm efficacy of the gold compound auranofin on dual species biofilms of <i>Staphylococcus aureus</i> and <i>Candida</i> sp.

Gold(I) ion and the phosphine ligand are necessary for the anti- Toxoplasma gondii activity of auranofin

Study of metalation of thioredoxin by gold(I) therapeutic compounds using combined liquid chromatography/capillary electrophoresis with inductively coupled plasma/electrospray MS/MS detection

Structural basis for the inhibitory mechanism of auranofin and gold(I) analogues against Pseudomonas aeruginosa global virulence factor regulator Vfr

Sublethal Auranofin Potentiates Tumor Responses to ATR Inhibition by Inducing Oxidative DNA Damage Selectively in Cancer Cells

Interaction between Cu and Thiols of Biological and Environmental Importance: Case Study Using Combined Spectrophotometric/Bathocuproine Sulfonate Disodium Salt Hydrate (BCS) Assay

Flavoenzyme-catalyzed Formation of Disulfide Bonds in Natural Products.